NEULANDLAB

Neuland Laboratories Limited announced that its management will participate in the 360 ONE Capital(B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 in Mumbai on May 28, 2026. The meeting will include group and one-on-one sessions with analysts and institutional investors.

Management guided for an aspirational 18-20% CAGR over a 5-year period, expressing confidence in long-term growth driven by existing and new commercial molecules, particularly the significant $5-6 billion market opportunity in peptides. The company incurred a Capex outflow of INR397.1 crores in FY26 for large-scale peptide commercial facilities and a new R&D center, with the peptide facility on track to be operational by July. While FY26 free cash flow was negative due to investments and increased working capital (expected to normalize in FY27), the balance sheet remains strong with negative net debt. Management acknowledges quarterly business lumpiness and supply chain volatility but focuses on execution discipline and strategic capital allocation for future expansion.

Neuland Laboratories Limited announced the availability of the audio recording of its earnings call, which was conducted on May 12, 2026. The call discussed the financial results for the quarter and year ended March 31, 2026. A weblink to access the recording has been provided.

For the year ended March 31, 2026, Consolidated Revenue from operations increased to ₹2023Cr vs ₹1477Cr (▲37% YoY), EBITDA to ₹575Cr vs ₹410Cr (▲40% YoY), and PAT to ₹364Cr vs ₹260Cr (▲40% YoY). EBITDA Margin expanded to 28.4% vs 27.7% (▲65bps). The company recommended a final dividend of Rs. 34/- per equity share for FY2025-26 and approved a capacity enhancement of 120.5 KL at Unit 1 with a ₹143.4 crore investment, to be completed in 12-18 months.

Consolidated Revenue ₹788.7Cr vs ₹335.8Cr (▲134.9% YoY), EBITDA ₹319.4Cr vs ₹58.2Cr (▲448.6% YoY), PAT ₹212.5Cr vs ₹27.7Cr (▲666.3% YoY). EBITDA Margin 40.5% vs 17.3% (▲2316bps).

Neuland Laboratories reported strong Q4FY26 results: Total Income ₹788.7 Cr vs ₹335.8 Cr (▲134.9% YoY), EBITDA ₹319.4 Cr vs ₹58.2 Cr (▲448.6% YoY), PAT ₹212.5 Cr vs ₹27.7 Cr (▲666.3% YoY). EBITDA Margin expanded significantly from 17.3% to 40.5% (▲2316bps). Management expressed satisfaction with ending FY26 on a strong note, in line with expectations, and noted good business visibility.

Neuland Laboratories Limited's Board approved the Audited Annual Financial Results for FY 2025-26 and recommended a final dividend of Rs. 34/- (340%) per equity share. The company plans to enhance capacity at Unit 1 by 120.5 KL, investing ₹143.4 crores over 12-18 months to meet growing demand. Dr. Mauricio Futran was appointed as an Additional Director.

The Board approved the Audited Financial Results for the year ended March 31, 2026, and recommended a final dividend of Rs. 34/- (340%) per equity share for FY 2025-26. Dr. Mauricio Futran was appointed as an Additional Director. The 42nd Annual General Meeting (AGM) will be held on August 4, 2026, with July 24, 2026, as the record date for the dividend. The company also approved a capacity enhancement of 120.5 KL at Unit 1, requiring an investment of ₹143.4 crores, to be completed within 12-18 months.

Neuland Laboratories Limited's Board approved Audited Annual Financial Results for FY2025-26 and recommended a final dividend of Rs. 34/- per equity share. To meet growing demand, the company announced a capacity enhancement of 120.5 KL at Unit 1 with an investment of Rs. 143.4 crores, funded by internal accruals and borrowings. Dr. Mauricio Futran was also appointed as an Additional Director.

Neuland Laboratories' Board approved annual financial results for FY2025-26 and recommended a final dividend of Rs. 34/- (340%) per equity share. Dr. Mauricio Futran was appointed as an Additional Director (Non-Executive Non-Independent) effective May 12, 2026. The company announced a capacity expansion at Unit 1 by 120.5 KL, investing ₹143.4 crores, to be completed in 12-18 months to meet growing demand. The 42nd AGM is scheduled for August 4, 2026, with July 24, 2026, as the record date.

Consolidated Total Income ₹788.7Cr vs ₹335.8Cr (▲134.9% YoY), EBITDA ₹319.4Cr vs ₹58.2Cr (▲448.6% YoY), PAT ₹212.5Cr vs ₹27.7Cr (▲666.3% YoY). EBITDA Margin 40.5% vs 17.3% (▲2320bps). Management highlighted strong performance in line with expectations, good business visibility, and investments in Peptide Manufacturing and a new R&D Centre for future growth.

Consolidated Revenue for the quarter ended March 31, 2026, was ₹788.71Cr vs ₹335.82Cr (▲134.89% YoY), EBITDA ₹307.33Cr vs ₹51.07Cr (▲501.74% YoY), PAT ₹212.67Cr vs ₹27.81Cr (▲664.12% YoY). EBITDA Margin expanded to 38.97% vs 15.21% (▲2376bps). The Board also recommended a final dividend of ₹34 per share for FY26 and approved a capacity expansion project of 120.5 KL at Unit 1 with an investment of ₹143.4 crores.

Consolidated annual results for the year ended March 31, 2026: Revenue from operations ₹2,022.99 Cr vs ₹1,476.84 Cr (▲37.0% YoY), EBITDA ₹574.50 Cr vs ₹399.66 Cr (▲43.7% YoY), PAT ₹364.00 Cr vs ₹260.11 Cr (▲39.9% YoY). EBITDA Margin 28.39% vs 27.06% (▲133bps). The board recommended a final dividend of ₹34/- per equity share for FY26 and approved a 120.5 KL capacity expansion at Unit 1 with a ₹143.4 Cr investment to meet growing demand.